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Ideal Experimental Rat Models for Liver Diseases
There are many limitations for conducting liver disease research in human beings due 
to the high cost and potential ethical issues. For this reason, conducting a study that 
is difficult to perform in humans using appropriate animal models, can be beneficial 
in ascertaining the pathological physiology, and in developing new treatment modalities. 
However, it is difficult to determine the appropriate animal model which is suitable for 
research purposes, since every patient has different and diverse clinical symptoms, 
adverse reactions, and complications due to the pathological physiology. Also, it is not 
easy to reproduce identically various clinical situations in animal models. Recently, the 
Guide for the Care and Use of Laboratory Animals has tightened up the regulations, 
and therefore it is advisable to select the appropriate animals and decide upon the 
appropriate quantities through scientific and systemic considerations before conducting 
animal testing. Therefore, in this review article the authors examined various white rat 
animal testing models and determined the appropriate usable rat model, and the pros 
and cons of its application in liver disease research. The authors believe that this review 
will be beneficial in selecting proper laboratory animals for research purposes.
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Introduction
  There are many limitations in conducting liver disease 
research directly in human beings due to the high cost, and 
particularly due to the potential ethical issues.1 In other 
words, conducting a study that is difficult to perform in 
humans using appropriate animal models, can be advan-
tageous in ascertaining the pathological physiology and in 
developing new treatment modalities.2 Nevertheless, it is 
difficult to determine the appropriate animal model which 
is suitable for research purposes, since every patient has 
different and diverse clinical symptoms, adverse reactions, 
and complications due to the pathological physiology. Also, 
identical reproduction of various clinical situations in 
animal models may not be feasible. Recently, the 
Guidelines for the Care and Use of Laboratory Animals has 
become stringent, and therefore it is advisable to select the 
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Table 1. Animal pharmacology companies and their web sites
Company Web site
The Jackson Laboratory
Charles River Laboratories, Inc.
Harlan Laboratories, Inc.
Central Lab. Animal, Inc.
Orient Bio, Inc.
Nara Biotech, Inc.
Koatech
Samtako Bio Korea, Inc
DBL, Inc.
http://jaxmice.jax.org/index.html
http://www.criver.com/
http://www.harlan.com/products_and_services/research_models_and_serv
ices/research_models_by_product_type
http://www.labanimal.co.kr/product/slc08.html
http://www.orient.co.kr/p1_1.asp
http://www..narabio.co.kr/
http://www.koatech.co.kr/
http://www.samtako.com
http://www.dbl.co.kr
appropriate animals and decide upon the appropriate 
quantities through scientific and systemic considerations 
before conducting animal testing. 
  Therefore, in this review article we attempted to search 
various rat animal experimental models, and to determine 
the appropriate usable rat model, and investigate the pros 
and cons of its application in liver disease research. We 
believe that this review will be beneficial in selecting 
proper laboratory animals for research purposes.
Acquisition of the Experimental 
Animal Model
  Many animals are utilized in studies of disease 
development process and biochemical studies, in humans. 
The majority of animal models have dissimilar explanations 
for the conditions or diseases that occur in humans, but 
they are absolutely essential for the advancement of 
physiomedical knowledge. The basic criteria for an ideal 
experimental animal model are as follows:3-5
  1) It should accurately reproduce the disease that is 
being researched. 
  2) It should be accessible to many researchers.
  3) It should be exportable to other laboratories.
  4) It should be adequate enough to provide an 
appropriate quantity of samples.
  5) It should be easily handled by researchers. 
  6) It should survive long enough to be usable.
  7) It should adapt well to the breeding environment.
  8) It should be available in multiple species.
  9) It should be in a polytocous species.
  Animal disease models are divided into two types: 
spontaneous and experimentally induced models. Sponta-
neous animal models can be used as human disease 
models. These models resemble the human disease 
compared to experimentally induced models. Experi-
mentally induced models can be created either through 
surgical modifications, genetic modifications, chemical 
modifications, and biological modifications. The classic 
examples of experimentally induced models are chemically 
induced diabetes models and neoplastic models, which 
have been reported to be used in many studies. Recently, 
the genetically engineered models have emerged as the 
most prevalent experimentally induced model, but their 
application are more common in mice than in rats. 
However, for surgical experimentation, rats are preferred to 
mice as rat is larger and therefore is more advantageous 
and ideal. The above mentioned ideal conditions for animal 
experiments are also applicable to rats, and rats which meet 
the animal model criteria are procured easily from supply 
companies (Table 1). Examples of the more common 
species of rats used in animal models are Wistar, 
Sprague-Dawley, Osborne- Mendel, Long-Evans, Holtzman, 
Slonaker, and Albany. 
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Table 2. The classification of rat models for liver diseases
Type of 
animal model Animal designation Animal origin or manipulation
Human Disease 
reproduced
Genetically 
 determined
Iatrogenically 
 produced
Gunn rat
LEC rat
Nagase analbuminemic rat
Rats
Rats
Spontaneous mutation
Spontaneous mutation
Spontaneous mutation
Administration of Acetaminophen, CCl4, d-galactosamine,
 other chemicals, subtotal partial hepatectomy
Repeated CCl4 administration
Crigler-Najjar syndrome
Wilson’s disease
Analbuminemia 
Acute liver failure
Liver cirrhosis
Rat Strains 
  In 1959, Billingham RHK and Silvers first defined the rat 
species, and more than 220 species of inbred strains and 
many substrains are now present.6 
  Inbreeding is defined as 20 or more times of breeding 
between offsprings or between parents and offspring, and 
since this is a highly genetically isogenic strain, a ‘unique 
species’ reaction may be obtained. In outbreeding, 
breeding is continued within a specified group which is less 
closely related than that in inbreeding, and was originally 
derived from inbreeding. Although in outbreeding, the 
uniformity of genetic composition is less consistent than in 
inbreeding animals, the reproduction rate is higher and 
breeding is relatively easy, and therefore outbred animals 
play an important function in biological examination. 
Liver Disease Experimental 
Animal Models
1. Types of liver disease experimental animal 
models
  The liver disease experimental animal models are divided 
into 2 types (Table 2). 
  The first category is the genetically determined disease 
model. Examples of genetically determined disease models 
are the Gunn rat in which there is deficient bilirubin 
metabolism (Crigler-Najjar syndrome),7 the Long-Evans 
Cinnamon (LEC) rat in which there is deficient copper 
metabolism (Wilson’s disease),8 and rats with deficient 
albumin production; the Nagase analbuminemic rat (NAR), 
and the analbuminemic congenic strains of rats; ACI-alb, 
F344-alb and SHR-alb.9 Others examples are the 
spontaneously hypertensive rat (SHR), the diabetic rat 
(OLETF), and the obese rat (Zucker rat). 
  The second type of experimental animal models com-
prises of the drug induced or surgically induced models. 
2. Metabolic liver disease animal models
  Metabolic liver disease animal models were developed by 
genetic mutations as they share various clinical charac-
teristics, side effects, complications in humans according to 
the individual pathological physiology.
  1) Gunn rat (Crigler-Najjar syndrome)
  Protoporphyrin moiety of heme proteins such as bilirubin 
and hemoglobin, is a toxic derivative. For its elimination 
from the serum, bilirubin conjugates with glucuronic acid, 
and UGT1A1 (bilirubin UDP-glucuronosyltransferase) is the 
sole isoform of bilirubin glucuronidating UGT1 in humans 
or rats.10 Genetic variations in the gene encoding UGT1A1 
lead to complete or partial inactivation of the glucuroni-
dation of bilirubin in the serum, which causes unconjugated 
bilirubin. This may lead to the development of hyper-
bilirubinemic conditions such as the Crigler-Najjar (CN) 
Syndrome in humans.11 
  The liver parenchyma and thousands of other metabolic 
functions are normal in the patients with this disease, but 
they are at risk of severe neurologic complications. 
Orthotopic liver transplantation is the radical treatment 
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Fig. 1. Natural History of the LEC
rat.19
method,12,13 but this procedure corrects only one enzyme 
deficiency when all other liver functions are normal. In 
clinical practice, retransplantation is necessary in up to 15% 
of patients after liver transplantation, and progressive 
fibrosis of the transplanted liver over long- term is a major 
concern.14 
  Gunn rats are derived from the Wistar species and cause 
unstoppable elevations of serum bilirubin leading to uncon-
jugated hyperbilirubinemia. The Gunn rats inherently lack 
all the glucuronidation activity catalyzed by the UGT1 
isoform. Therefore, these rats are used in the animal 
experiment models for investigation of type I Crigler-Najjar 
(CN) syndrome.15,16
  2) Long Evans Cinnamon (LEC) rat (Wilson’s disease)
  The LEC rat was discovered in 1983 at the Center for 
Experimental Plants and Animals, Hokkaido, Japan, and is 
characterized by the unique cinnamon colored fir, and is 
similar to the mutation form of the Long-Evans rat.17 The 
LEC rat is an appropriate animal model for the study of the 
importance of hepatitis in the development of hepatomas.18,19 
The species with this mutation self expresses chronic 
hepatitis followed by an extremely high incidence of 
preneoplastic lesions and hepatomas (Fig. 1).
  That is, the LEC rat shows a remarkable similarity to the 
clinical course of liver cancer development in humans. 
Recently, the spontaneous hepatitis shown in LEC rats is 
thought to be related to high copper accumulation in the 
liver, and this is probably due to the problems in the 
excretion of copper from the blood and bile by the liver. 
Therefore, the occurrence of liver cancer can be controlled 
by reducing the copper content in the feed provided to the 
laboratory animals, and it can theoretically be deduced 
whether liver cancer develops in association with hepatitis. 
Also, in the LEC rat model, hepatitis causes a high mortality 
rate and abnormal copper metabolism, which makes the 
animal suitable to serve as an animal model of individual 
human fulminant hepatitis and Wilson’s disease. The 
spontaneous hepatitis in LEC rats is characterized by a 
sudden onset at 4 months after birth. Therefore, the LEC 
rat is the ideal model for studying the role of hepatitis in 
the pathogenesis of liver cancer. Excessive accumulation of 
copper in the liver has been confirmed to lead to hepatitis. 
The excretion of dietary copper into blood and bile is 
affected, and as a result copper accumulates in the liver 
cells. The treatment or control of copper in the animal feed 
with chelating agents, such as D-penicillamine or trientine, 
will accelerate hepatitis in LEC rats. In many preliminary 
studies, it has been shown that lowering the concentrations 
of copper in the animal feed adequately prevents the 
occurrence of hepatitis, and high concentrations of copper 
will lead to hepatitis induction.20 This phenomenon may 
explain the regulatory mechanisms of the sequential liver 
cancer process, by the prevention or acceleration of 
hepatitis. 
  Furthermore, the LEC rat is an appropriate animal model 
for Wilson’s disease. It mimics the human Wilson’s disease 
in its characteristics such as excessive copper accumulation 
in the liver and low levels of serum ceruloplasmin, low 
excretion of copper into the bile.16,21 The key defect that 
causes such abnormal copper metabolism has not been 
elucidated in Wilson’s disease, and the research for the 
gene responsible for hepatitis in LEC rats may provide a 
clue to the pathogenesis of Wilson’s disease. However, in 
LEC rats, copper deposition does not occur in the brain or 
cornea, and therefore the pathognomonic signs of Wilson’s 
disease such as hepatolenticular degeneration of the brain, 
Sang Woo Lee, et al：Ideal Experimental Rat Models for Liver Diseases
71
or Kayser-Fleischer ring of the cornea are absent in LEC 
rats, and hence this condition is not exactly identical with 
human Wilson’s disease. 
  3) Nagase analbuminemic (NAR) rat (Analbuminemia)
  Analbuminemia in humans was first described by 
Benhold. In 1959, and the etiology and metabolic aspects 
of this condition have been studied by other researchers.22 
Increased levels of globulin accompanying albumin 
decrease have been reported in the serum of 
analbuminemia patients, along with high levels of 
cholesterol.23 
  In 1977, Nagase and Shimamune discovered the analbu-
minemic rat by mating hypercholesterolemic Sprague- 
Dawley rats, and named it the Nagase analbuminemia rat 
(NAR). NAR not only displays analbuminemia but also 
hyperlipidemia, which comprises of very high serum levels 
of cholesterol as well as triglycerides, and thus the 
analbuminemic rat is an appropriate model for studying 
hyperlipidemic conditions. Thioacetamide (TA) is usually 
used for induction of liver cirrhosis but sustained TA 
administration does not seem to elicit liver cirrhosis in the 
NAR.24 A the cellular level, cholangiolar proliferation occurs 
as a result of the mechanism of TA toxicity. In other words, 
it would appear that liver cirrhosis may inherently prevent 
hyperlipidemia and hypercholesterolemia in the NAR, 
which holds a potential for its clinical application in the 
treatment of liver cirrhosis.24
  4) Other analbuminemic rats
  In 1986, Nagase utilized ACl, F344, SHR (spontaneous 
hypertensive rat) to develop the analbuminemic syngeneic 
white rat. This animal was produced by repeated back-
crossing, and with the exception of the albumin genes, 
expresses inbred fir color and biochemical genes. 
Compared to the rat presenting albumin, the liver and 
adrenals of analbuminemic syngeneic white rat show 
increase in weight from 30 weeks onwards. Also, the serum 
lipid levels appear to be higher at the same time.25
  5) Eisai hyperbilirubinemic rats (Hyperbilirubinemia)
  Eisai hyperbilirubinemic rat (EHBR) is a Sprague-Dawley 
(SD) rat mutant with conjugated hyperbilirubinemia as an 
autosomal recessive trait.26 EHBR manifests jaundice from 
birth, which is permanent except for a transient decrease 
in bilirubin levels at 6∼8 weeks of age. EHBR is thus a 
useful animal model for studying the biliary excretion of 
bilirubin. In this animal model, there was unstable biliary 
excretion of organic anions such as sulfobromophthalein, 
indocyanine green and glutathione conjugates.26-29 In recent 
studies, TCA (tricarboxylic acid) cycle defect in biliary 
excretion has been observed in EHBR models.29,30 However, 
the results of this study, in which a spontaneous model was 
employed, may explain the altered bile secretion in EHBR 
models. That is, hyperbilirubinemia and high serum bile 
acid levels may hinder bile acid excretion in vivo. 
  6) Albumin-deficient and Jaundiced rat (AJR)
  In 1981, Nagase and Shumiya developed the albumin- 
deficient and jaundiced rat (AJR) strain by hybridization of 
albumin-deficient rats and jaundiced Gunn rats. These 
animals are characterized by double homozygosity and 
systemic jaundice and various neurological signs are 
observed 5∼7 days after birth. Kernicterus occurs and the 
animal dies within 3 weeks after birth. This animal model 
can be used for research of human kernicterus and bilirubin 
metabolism.31
3. Acute liver failure animal model
  Terblanche and Hickman formulated the following 
requisite conditions in studies with animal models of acute 
liver failure.5 
  First, the degree of acute liver failure must be reversible 
so that survival is likely after effective therapy.
  Second, identical death rates should be reproducible 
when inconsistent treatment is given.
  Third, selective liver damage must be the cause of death.
  Fourth, a therapeutic window must be obtained.
  Fifth, the animal must be large enough so that the 
treatment can be administered in humans.
  Sixth, the hazard to the studying person should be 
minimized.
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  The six standards suggested above are known as the 
basic requisites for animal models of acute liver failure. 
Newsome suggested 2 additional items.4
  Seventh, the animal model should have metabolic or 
physiological mechanisms similar to that in humans.
  Eighth, animal experimental methods should adhere to 
appropriate ethical standards.
  1) Surgical models 
  Surgical animal models are classified into 3 types; 
anhepatic model, partial hepatectomy model, and the 
devascularization model. 
  (1) Anhepatic model: In this model the liver is completely 
removed, and it carries the disadvantage that death of all 
animals ensues if transplantation is not performed. 
Furthermore, the duration of hepatic coma is short and is 
different from the pattern in human patients, and the use 
of this model is limited since the liver cells that are 
damaged or necrotized are not exposed to the vascular 
circulation.32
  (2) Partial hepatectomy (PH) model: In the partial hepatec-
tomy model, excellent liver regeneration and survival has 
been observed in 100% of models after early removal of 
70% of the liver.33 Thereafter, an increase in mortality rates 
was demonstrated due to an increase in the resection rate 
which leads to increased portal circulation and endothelial 
cell damage, and also activation of Kupffer cells and 
increased secretion of cytokines that induce acute liver 
failure. The increased portal flow per liver tissue also 
increases the endotoxemic load in the gastrointestinal 
tract.34 In this model, late hypoglycemia occurs and the pH 
is maintained at 7.3±0.03. The identical death rates are 
reproducible. The limitation of this model is the lack of 
clinical patterns that manifest in humans. Late hypoglycemia 
develops, and therefore reproducibility is low and irrever-
sible. 
  (3) Devascularization model: Mechanisms of injury due to 
devascularization are at present known to be very complex.35 
In ischemic damage, suppression of oxidative phosphory-
lation leads to decreased ATP and defects in mitochondrial 
respiratory chain. This affects the intracellular calcium 
homeostasis which in turn affects the kinase activity which 
is the cause of injury to protein, lipid and DNA. Conse-
quently, the reperfusion injury may cause a major injury, 
which produces reactive oxygen species (ROS) and 
hydroxyl radicals. This reaction activates the amplified 
cascade in the Kupffer cells, which subsequently results in 
lipid peroxidation, protein damage, complement activation, 
and finally apoptosis or necrosis.36-39 
  Partial devascularization can be performed by the 
insertion of a portacaval shunt and temporally graded 
clamping of the hepatic artery. Complete devascularization 
model of acute hepatic failure is used. But, this is an 
irreversible model and this is similar to the anhepatic 
model. This model is developed by portacaval shunting or 
hepatic artery ligation. 
  2) Bile duct ligated model
　The first description of the comprehensive bile duct 
ligated model was in the early 1930s by Cameron and 
Oakley. Based on this report, comprehensive bile duct 
ligated model was established by Kountouras et al in 1984,40 
and this model became increasingly employed in research 
involving other aspects of liver fibrosis. Thereafter until the 
early 1990s, bile duct ligation induced fibrocirrhotic disease 
was focused in studies on histological changes. In a recent 
series by Chang et al., liver cirrhosis was induced by 
administration of various hepatotoxins and bile duct 
ligation, and the comparative results were reported.41 The 
bile duct ligated model attempted to produce necrosis and 
fibrosis, and cirrhosis similar to liver cirrhosis induced by 
administration of many types of hepatotoxins, but it failed 
to produce lipid changes. Also, bile duct ligated model 
differs from other animal models in which liver cirrhosis 
was induced in all animals after 4∼8 weeks. Thus, bile 
duct ligation is the quickest and most consistent method for 
inducing fibrocirrhotic disease of the liver. 
  3) Toxic drug model
  Hepatotoxic drugs that induce hepatic failure are widely 
employed. Drugs that have been utilized over the past 30 
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years are D-galactosamine (D-Gal), acetaminophen (parace-
tamol/APAP), carbon tetrachloride (CCl4), and Thioace-
tamide (TAA). Concanavalin A (Con A) and lipopoly-
saccharide (LPS) are the other drugs that have emerged 
recently. However, toxic drug reaction differs according to 
different species, or even between individual models of the 
same species, and therefore it is difficult to attain high 
reproducibility rates.
  (1) D-galactosamine: Keppler was the first to describe the 
hepatotoxic properties of D-Gal in rats in 1968.42,43 D-Gal 
is an amino sugar that is metabolized in the liver and 
causes uridine nucleotide depletion and hepatic trans-
criptional blockade. It cannot be said that the depressed 
protein synthesis by D-Gal induces hepatic failure. The 
cause of hepatic failure has been proposed in a study 
which revealed that, in hepatic transformation there are 
other stimuli which partially reflect the role of chemicals 
including uridine.44 It is thought that the administration of 
D-Gal induces portal endotoxemia that containes intestinal 
endotoxins. Also, D-Gal hepatitis in rats can be prevented 
by colectomy and neutralization of LPS by polymyxin B, or 
the induction of endotoxin tolerance. This concept 
continues to expand, and there is evidence that TNF-α acts 
as a terminal mediator.45 This is related to the significant 
cellular necrosis that occurs after D-Gal administration. 
There exists a difference in the susceptibility between 
different species. While the rat is sensitive to D-Gal, mice 
show resistance even after high-dose D-Gal administration 
at 1 g/kg.46 
  (2) Acetaminophen: In the United Kingdom, acetamin-
ophen abuse is the most common cause of acute liver 
failure. In other countries such as France and the United 
States, the frequency of acetaminophen abuse is rapidly 
increasing.47 Acetaminophen metabolism occurs in the liver. 
Under normal conditions, acetaminophen glucuronidation 
and sulfation leads to biotransformation and excretion. If 
this mechanism becomes overloaded then acetaminophen is 
metabolized by the cytochrome P450 oxidative enzyme.48-51 
Subsequently this results in the production of a toxic 
metabolite N-acetyl-p-benzoquinoneimine (NAPQI), by 
non-conjugation of acetaminophen with endogenous gluta-
thione.52-54 The toxic properties of NAPQI have been 
attributed to the formation of free radicals, reactive oxygen 
species, hydroxyl radicals, nitrites and nitrates, which 
obstruct the mitochondrial calcium channel and cell 
injury.55 This chain reaction is amplified by the production 
of cytokines and free radicals that cause apoptosis and 
necrosis of Kupffer cells. This is characterized particularly 
by the adequate presence or absence, efficiency, species 
diversity and senility of the cytochrome P450 oxidative 
enzyme.56-58 2E1 and 1A2 are the members of the 
cytochrome P450 family that are the most closely related 
to acetaminophen metabolism. To date many models are 
being researched to establish an acetaminophen model. 
  (3) Carbon tetrachloride (CCl4): The hepatotoxic properties 
of CCl4 have been known for a long period of time.59,60 
CCl4 was extensively employed in acute liver injury models 
in the 1970s and the early 1980s, but after it was revealed 
that reproducibility was not up to the desired standards, 
along with questions regarding species diversity,61,62 it was 
not used further. Recently, a model has emerged in which 
CCl4 is administered into the stomach and intraperitoneally 
to induce liver cirrhosis.63,64 The cytochrome P450 enzyme 
is considered to participate in the production of CCl4 
metabolites.59,65,66 In 1972, it was postulated by Chopra et 
al that the induction process of P450 enzyme increased 
CCl4 toxicity, and it was further ascertained by Nayak in 
1970 and 1975 who demonstrated phenobarbitone toxicity 
in rat fetuses, neonates, and adults by comparing P450 
enzyme activity between an induction group and control 
group. The results were very interesting; the fetal model 
in the 2 groups did not demonstrate necrosis. In neonatal 
rats induced with P450 enzyme, the cellular characteristics 
observed were ballooning, centrilobular necrosis, and 
Councilman bodies, suggesting a small degree of injury in 
the control group. In contrast, injury in adult rats was 
extensive and was proportional to the dose of the CCl4 
administered. However, this was also true for the induction 
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group, and the production of free radicals is suggested as 
one of the mechanisms involved.66-68 Homolytic dissolution 
of haloalkanes occurs in the liver microsomal P450 which 
produces trichloromethyl that reacts with reactive oxygen 
species to produce active metabolites. These metabolites 
combine with macromolecules to increase peroxidation, 
and cellular injury by disruption of intracellular calcium 
homeostasis. In more recent studies, the mechanism of 
CCl4-induced cell death is explained to be the same as in 
necrosis, and is the consequence of apoptosis. Shi et al. 
explained apoptosis of cells in CCl4-only treated rats using 
light electron microscopy and nuclear DNA fragment 
patterns and immunohistochemical labeling and flow 
cytometry analysis. The majority of apoptotic cells are 
located in the centrilobular region of the liver. The kidneys 
are also sensitive to CCl4 and acute tubular necrosis 
develops after exposure to CCl4.69,70 Clinically, manife-
stations of acute liver failure such as early encephalopathy 
and late stage hepatic coma are not easily produced by 
CCl4 toxicity, and therefore this model is rarely used in 
investigating acute liver failure. 
  (4) Thioacetaminophen (TAA): Thioacetamide (TAA) has 
also been used in the past for induction of acute hepatic 
failure. TAA induces TAA-S-oxide transformation by 
mechanisms of flavine adenine dinucleotide containing 
monooxygenase and causes cell necrosis by biotransfor-
mation into metabolites,71 and is thought to cause apoptosis 
at low concentrations. However, if the doses are increased, 
electrophiles and free radicals are released which contribute 
to lipid peroxidation and centrilobular necrosis and are 
then expelled.72 TAA is widely employed as an agent to 
induce acute liver failure in rats and mice, but it has been 
suggested that the use of other animals may lead to species 
variability. In models using rabbits there is definite 
variability with respect to clinical and histological change. 
Clinical characteristics such as encephalopathy, metabolic 
acidosis, high levels of transaminase, abnormal coagulo-
pathy, and centrilobular necrosis were observed after 
intraperitoneal TAA administration in rats, and these 
manifestations reached their peak after 12∼24 hours.72-74 
Administration doses ranged from 400 mg/kg to 600 mg/kg, 
and intervals varied from once a day for 2 days to once 
a day for 3 days. Recent reports have successed to show 
liver cirrhosis development after chronic administration of 
TAA.64,75,76 The authors of this review have also 
experienced induction of liver cirrhosis via various routes 
of TAA administration.77
Conclusions
  Animal model experiments have recently contributed to 
proof of theories and delineation of the pathophysiology. 
It is of utmost importance to gain accurate knowledge via 
various animal experiments for an appropriate selection of 
the ideal animal model for research. High reproducibility 
and simple animal models that will provide high quality 
research will contribute to our academic development. 
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